The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11) Haematologica Wasag et al. 96: 922
Disclosures and Contributions
Files in this Data Supplement: